HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.
Quote:
Login Free Membership
Search:

 
Press Releases  

Zacks Analyst Blog Highlights: Eli Lilly & Co., Wells Fargo, Bank of America Corporation, Citigroup, Inc. and JPMorgan Chase & Co.

October 22, 2009 | Comments: 0
Recommended this article (1)
LLY | WFC | BAC | C | JPM
Print    Share

For Immediate Release

Chicago, IL – October 22, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly & Co. (LLY - Analyst Report), Wells Fargo (WFC - Analyst Report), Bank of America Corporation (BAC - Analyst Report), Citigroup, Inc. (C - Analyst Report) and JPMorgan Chase & Co. (JPM - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s AnalystBlog:

Eli Lilly Beats, Raises Guidance

This morning, Eli Lilly & Co. (LLY - Analyst Report) reported strong third quarter financials. The company’s earnings per share of $1.20 surpassed the Zacks Consensus Estimate of $1.02 and 98 cents reported in the year-ago period. Revenues recorded a 7% year on year increase to $5.56 billion, driven by an increase in both volume and prices, partially offset by unfavorable impact of foreign exchange.

Of total revenues, while product sales were $5.4 billion (an increase of 6%), collaboration and other revenues accounted for the remaining $176.5 million (an increase of 51%), primarily due to the inclusion of Erbitux revenue as a result of the ImClone acquisition.

The company’s other products recorded robust growth during the quarter compared to the year-ago period – Zyprexa (3% growth to $1.2 billion), Cymbalta (10% growth to $790.2 million), Humalog (16% growth to $500 million), Alimta (47% growth to $462 million).

Wells Fargo Surprises Yet Again

Before the market opened Wednesday morning, Wells Fargo (WFC - Analyst Report) reported third quarter 2009 diluted earnings of 56 cents per common share, compared with 57 cents in the second quarter 2009 and 49 cents in the third quarter 2008.

Net income applicable to common shareholders came in at $2.6 billion, almost flat compared with the prior quarter and up 61.1% year-over-year. The results were substantially ahead of the Zacks Consensus Estimate of 35 cents per share.

Results were aided by strong top-line growth across all key business segments, strong deposits and a robust loan growth rate. Unlike its major peers, Wells Fargo witnessed strong growth in its traditional banking operations, especially in its mortgage business acquired from Wachovia. Net interest income of $11.7 billion climbed 83.1% year-over-year.

However, credit quality deteriorated further and losses rose sharply during the quarter. The bank expects credit losses and non-performing assets to increase further, though some moderation was visible. Net charge-offs rose to $5.1 billion (2.50% of average loans) from $4.4 billion (2.11%) in the prior quarter and $2.0 billion (1.96%) in the prior-year quarter. Non-performing assets grew to $23.5 billion (2.93% of loans) from $18.3 billion (2.23%) in the prior quarter and $6.2 billion (1.53%) in the prior-year quarter.

Credit-loss provisions were $6.1 billion, up 144.9% from a year earlier and 20.2% from the prior quarter. The allowance for credit losses totaled $24.5 billion at Sept. 30, 2009, compared with $23.5 billion at June 30, 2009 and $8.0 billion at Sept. 30, 2008.

Large banks including Wells Fargo, Bank of America Corporation (BAC - Analyst Report), Citigroup, Inc. (C - Analyst Report) and JPMorgan Chase & Co. (JPM - Analyst Report) have suffered from the increase in loan losses which were offset by strong growth in trading operations.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

 

 


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Nov 21, 2009 22:49 pm ET
DJIA 10318.16  -14.28 -0.14%
NASD 2146.04  -10.78 -0.50%
S&P 500 1091.38  -3.52 -0.32%
Sponsored Links